On 29 December, 2023, China Medical System Holdings Limited (“CMS”) is pleased to announce that PharmaGend Global Medical Services Pte. Ltd. (“PharmaGend”), jointly invested by CMS, through its wholly-owned subsidiary CMS MEDICAL VENTURE PTE. LTD., and its non-wholly owned subsidiary Rxilient Health Pte. Ltd., with Pharmaron (Hong Kong) International Limited (“Pharmaron”) * and HEALTHY GOAL LIMITED (“Legend Fund”), has entered into a lease agreement for the building and property located in Tuas, Singapore and completed the purchase of certain production machines and equipment from Strides Pharma Global Pte. Ltd. ( defined as “Singapore manufacturing plant ”). The Singapore manufacturing plant has advanced manufacturing machines, equipment and first-class infrastructure. It had been approved by Health Sciences Authority of Singapore (HSA), U.S. Food and Drug Administration (FDA) and Therapeutic Goods Administration of Australia (TGA). It will serve as the plant and site for PharmaGend to carry out pharmaceutical formulation, finishing, and packaging business, accelerating the […]
Recently, the fourth annual Environmental, Social, and Governance (ESG) Forum and Awards Ceremony hosted by Cailian Press ended successfully. China Medical System (“CMS”), with its long-term efforts and outstanding performance in the ESG field, was honored with the “2023 Cailian Press Zhiyuan Award – Pioneer in Corporate Governance.” The Cailian Press Zhiyuan Award aims to select representative companies that have business value and social influence in the ESG field and have contributed to the sustainable development. Specifically, the “Pioneer in Corporate Governance” award evaluates the comprehensive performances in corporate governance and selects companies with leading practices in ESG strategy, governance, profitability, competitiveness, and related honors. Upholding the ESG vision of becoming a world-leading sustainable pharmaceutical enterprise, CMS is dedicated to integrating sustainable development concepts into its overall strategy and daily operation. CMS has established a scientific and effective governance structure with clear responsibilities, and continuously promotes stakeholder engagement to optimize its internal […]
Recently, the innovative drug Diazepam Nasal Spray (VALTOCO) has issued its first prescription in the Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), which marks that the first Diazepam Nasal Spray in China has officially entered clinical application. It satisfies the unmet clinical needs of epilepsy emergency rescue outside the medical setting and brings a new acute treatment scheme for the seizure clusters/acute repetitive seizures of children and adults aged 6 and above with epilepsy. (Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences) issued the first prescription of Diazepam Nasal Spray (VALTOCO)) So far, three innovative drugs successfully approved for marketing this year have officially entered the national scale clinical application, marking another important milestone for the company to promote the commercialization of innovative products. On June 7, 2023, Diazepam Nasal Spray received approval from the National Medical Products Administration of China (NMPA). It is used for the seizure […]
On December 21, 2023, at the award ceremony of the “8th Global Investment Carnival” hosted by GuruClub, China Medical System (867.HK) stood out among over a hundred Hong Kong-listed companies with its sound business performance, outstanding innovation achievements and solid returns for shareholders, winning the award of ” Most Popular Southbound Stock Connect Company”, continuously enhancing its reputation in the capital market. The “Golden GuruClub Awards” annual outstanding company selection by GuruClub is one of the most influential rankings in the capital market. The ” Most Popular Southbound Stock Connect Company” award aims to commend listed companies with health corporate governance, leading industry position, promising business structure, and ability to provide sustainable and solid value returns for investors. Wining this award represents the capital market’s recognition of CMS’s outstanding performance this year. Since its listing on the main board of the Hong Kong Stock Exchange in 2010, CMS has been adhered to compliant operation and innovation development under continuously improved governance system. The company has maintained steady performance growth over years, with its annual compound growth […]
At 23:59 on December 18th, a M6.2 earthquake with a depth of 10 kilometers occurred in Jishishan County, Linxia Prefecture, Gansu Province. The earthquake affected 22 villages and towns in Qinghai Province within a range of 50 kilometers from the epicenter, causing casualties and property damage in many areas of Gansu and Qinghai. The disaster in this cold winter is touching the hearts of the whole nation. Merciless disaster, the world is love. The local governments and public welfare organizations attach great importance to this earthquake and provide necessary assistance and support to residents in the disaster area. CMS actively and rapidly responded to support the rescue work in the earthquake-stricken areas. After understanding the needs of the disaster area at the first time, CMS urgently purchased a batch of emergency relief materials, including Halal meals, cold-proof clothing, heating equipment, sanitary supplies, etc. CMS rushed to the rescue of Gansu and Qinghai with actual […]
The 10th CAAE International Epilepsy Forum hosted by the Chinese Anti-Epilepsy Association was grandly held in Nanchang from 15th to 17th December, 2023. Over 1700 authoritative experts from China and other countries/regions gathered together to exchange and discuss the hot topics in international epilepsy research and the frontiers of neuroscience, share academic feasts, and explore domain development. Adhering to its mission of providing competitive products and services to meet unmet medical needs, China Medical System (“CMS”) showcased its innovative drug Diazepam Nasal Spray (VALTOCO) at the conference. VALTOCO provides a more optimal and convenient choice for the acute treatment of cluster/acute recurrent seizures in domestic epilepsy patients. CMS’s Diazepam Nasal Spray (VALTOCO) Debuts at the 10th International Epilepsy Forum of CAAE Perseverance Leads to Success, Epilepsy Emergency Rescue Acquiring New Progress During the three-day conference, many scholars brought fascinating academic reports on the hot and difficult issues in current […]
Recently, China Medical System’s innovative drug ILUMETRI (Tildrakizumab Injection) has issued its first prescriptions for psoriasis patients who meet the treatment requirements in multiple hospitals located in different Chinese cities, including the Dermatology Hospital of the Chinese Academy of Medical Sciences, the Third Affiliated Hospital of Sun Yat-sen University, the Dermatology Hospital of Southern Medical University, and the First People’s Hospital of Foshan City. With the official launch of ILUMETRI’s nationwide drug supply, ILUMETRI officially stepped into large-scale clinical application, providing better choices for the long-term treatment and disease management among psoriasis patients in China. On May 26, 2023, ILUMETRI (Tildrakizumab Injection) was approved for marketing by the National Medical Products Administration of China for the treatment of adult patients who have moderate to severe plaque psoriasis and are suitable for systemic therapy or phototherapy. On December 13th, the “National Catalogue of Medicines for Basic Medical Insurance, Work Injury Insurance, […]
Innovative drugs VALTOCO (Diazepam Nasal Spray)，ILUMETRI (Tildrakizumab Injection) and rare disease drug Tetrabenazine Tablets have been newly included in China’s National Reimbursement Drug List(NRDL), XinHuoSu (Recombinant Human Brain Natriuretic Peptide for Injection) has continued to be included in NRDL. The Group actively responds to national policies to promote innovative products to be included in the NRDL. Up to now, 3 innovative drugs that have been approved for marketing (Diazepam Nasal Spray, Tildrakizumab Injection and Methotrexate Injection-psoriasis) have all been included in the NRDL, further improving the accessibility and affordability of the drugs and allowing innovative products to benefit more patients. The new/continued inclusion of the 4 products in the NRDL will be conducive to promoting the market coverage of the products and building professional brand power, and will have a positive effect on the Group’s business development. China Medical System Holdings Limited (“CMS” or “the Group”) is pleased to […]
China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the National Medical Products Administration (NMPA) has approved the application to conduct a clinical trial evaluating the safety and efficacy of Ruxolitinib Cream (the “Product”) for the treatment of non-segmental vitiligo on 11 December 2023. Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 14 million and 6.5 million vitiligo patients in China and the eleven Southeast Asian countries, respectively. Non-segmental vitiligo patients account for approximately 85% of them. If approved in Greater China and Southeast Asia, it may bring a novel therapeutic option to patients with non-segmental vitiligo in the area and satisfy the clinical need of topical drugs combining safety and efficacy. The Product is not approved by the NMPA for any indication in […]
On December 6th, the 8th Zhitong Finance Capital Market Annual Conference, jointly organized by Zhitong Finance and ROYALFLUSH INFO Finance, was grandly opened in Shenzhen. At the highly anticipated “Listed Company Selection and Awards” session, China Medical System Holdings Limited (“CMS”) (867.HK) was awarded the “Most Socially Responsible Listed Company” due to its high emphasis and active practices on social responsibility. The “Listed Company Selection” involved over a thousand listed companies, aiming to select outstanding examples among Hong Kong/US listed companies through rigorous indicator analysis, online voting, and expert evaluation. The “Most Socially Responsible Listed Company Award” aims to recognize listed companies that strive to practice social responsibility, actively fulfill their responsibilities towards consumers, communities, and the environment, and make positive contributions in areas such as charitable donations, targeted poverty alleviation, and ecological protection. For many years, CMS has been actively fulfilling the responsibilities and commitments of pharmaceutical […]
The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis indication of Methotrexate Injection. The Product is expected to become the first methotrexate (MTX) prefilled injection to treat RA by subcutaneous administration in China. The China bridge clinical trial of the Product’s RA indication reached the main endpoint; The results of secondary efficacy indicators suggest that the efficacy of the product is significantly better than that of MTX tablets or there is a trend of better. The product also has some advantages over MTX tablets in gastrointestinal safety. MTX is recognized internationally as the first choice first-line and anchor drug for RA. As a small-volume MTX prefilled injection with various strengths, the Product is expected to provide a safer, more effective, more convenient and more accurate administration scheme for active […]
